BerGenBio ASA (BRRGF) News Today $2.50 0.00 (0.00%) (As of 11/4/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlines All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Buy Rating Affirmed: Promising Safety and Efficacy Signals in BerGenBio’s NSCLC Treatment StudyOctober 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for BerGenBio ASA on Clinical and Strategic AdvancementsAugust 23, 2024 | markets.businessinsider.comBerGenBio ASA (7BG0.F)August 22, 2024 | uk.finance.yahoo.comBerGenBio First Quarter Results 2024: Advancing to the Next Stage of DevelopmentMay 29, 2024 | finance.yahoo.comBerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi®May 28, 2024 | finance.yahoo.comBerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutationMarch 20, 2024 | finance.yahoo.comBerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory InfectionsFebruary 7, 2024 | finance.yahoo.comGram Car Carriers Asa Share Price (GCC.OL)January 31, 2024 | lse.co.ukBerGenBio ASA (BRRGF) stock historical prices & data – Yahoo FinanceDecember 2, 2023 | sg.finance.yahoo.comBerGenBio ASA BGBIONovember 18, 2023 | morningstar.comBerGenBio Reports Third Quarter 2023 Financial ResultsNovember 14, 2023 | finance.yahoo.comBerGenBio Announces Data from Biomarker Analyses in 2L NSCLCNovember 6, 2023 | finance.yahoo.comBerGenBio Announces Poster Presentation at Upcoming SITC MeetingOctober 31, 2023 | finance.yahoo.comNew Data on BerGenBio's Selective AXL Inhibitor Bemcentinib Released Today at 2023 ESMO MeetingOctober 23, 2023 | finance.yahoo.comAdditional data on BerGenBio's selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meetingOctober 16, 2023 | finance.yahoo.comH.C. Wainwright Reaffirms Their Buy Rating on BerGenBio AS (BRRGF)August 23, 2023 | markets.businessinsider.comBerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung CancerAugust 22, 2023 | finance.yahoo.comCoronation concert ballot misleading, says regulator ASAAugust 15, 2023 | bbc.co.ukBerGenBio ASA: Approval and publication of prospectus for the preferential Rights IssueMay 26, 2023 | finance.yahoo.comBerGenBio AS (BRRGF) Gets a Buy from H.C. WainwrightMay 16, 2023 | markets.businessinsider.comBerGenBio ASA: Proposed partially underwritten rights issueApril 25, 2023 | finance.yahoo.comBerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11 MutationsMarch 9, 2023 | finance.yahoo.comBerGenBio ASA: BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC PatientsFebruary 17, 2023 | finanznachrichten.deBerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business UpdateFebruary 16, 2023 | finance.yahoo.comBerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC PatientsFebruary 15, 2023 | finance.yahoo.comBerGenBio reports third quarter 2022 financial results and provides business updateNovember 15, 2022 | finance.yahoo.comBerGenBio ASA Secures NOK 100 million Shareholder Loan Facility from Meteva ASOctober 25, 2022 | prnewswire.comBerGenBio Announces Initiation of Phase 1b/2a Trial Evaluating Bemcentinib in 1st line Non-Small Cell Lung Cancer Patients Harboring STK11 MutationsOctober 11, 2022 | finance.yahoo.comBERGENBIO ANNOUCES FIRST PATIENT RANDOMIZED IN BEMCENTINIB TRIAL IN EU-SOLIDACT PLATFORM FOR HOSPITALIZED COVID-19 PATIENTSSeptember 27, 2022 | finance.yahoo.comBGBIO.OL - Bergenbio ASA | Stock Price & Latest News | ReutersSeptember 10, 2022 | reuters.comBerGenBio reports second quarter and half year 2022 financial results and provides business updateAugust 23, 2022 | finance.yahoo.comBerGenBio strengthens its leadership team with appointment of Cristina Oliva as Chief Medical OfficerApril 11, 2022 | finance.yahoo.comBERGENBIO ASA: BOARD APPROVAL OF 2021 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2021April 7, 2022 | finance.yahoo.comBERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021February 16, 2022 | finance.yahoo.comBerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 PatientsJanuary 27, 2022 | finance.yahoo.comBRRGF Real-Time QuotesJanuary 21, 2022 | nasdaq.comBRRGF Price/Earnings & PEG RatiosJanuary 18, 2022 | nasdaq.comBergenbio Presents Pre-clinical and Clinical Data on Bemcentinib in STK11-positive NSCLC at SITC Annual Meeting 2021November 9, 2021 | finance.yahoo.comBerGenBio Receives FDA Fast Track Designation For Bemcentinib In STK11-mutated Advanced/Metastatic Non-small Lung Cancer (NSCLC)November 9, 2021 | finance.yahoo.com Get BerGenBio ASA News Delivered to You Automatically Sign up to receive the latest news and ratings for BRRGF and its competitors with MarketBeat's FREE daily newsletter. Email Address Countdown to the biggest trade of my 25 yr career (Ad)Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025. Click here to see the surprising reason why BRRGF Media Mentions By Week BRRGF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BRRGF News Sentiment▼0.000.45▲Average Medical News Sentiment BRRGF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BRRGF Articles This Week▼00▲BRRGF Articles Average Week Get BerGenBio ASA News Delivered to You Automatically Sign up to receive the latest news and ratings for BRRGF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AGNPF News Today AKBLF News Today DRTSW News Today ARNI News Today ASPHF News Today ASCLF News Today AVCTF News Today AWKNF News Today AXIM News Today BCTXW News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:BRRGF) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BerGenBio ASA Please log in to your account or sign up in order to add this asset to your watchlist. Share BerGenBio ASA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.